Radiation Oncology Resident at @YaleRadOnc | Alum: @waynemedicine, @FulbrightIT 🇮🇹, @ColumbiaBioethx, @BrownUniversity | He/Him
New Haven, CT
Joined August 2016
- Tweets273
- Following462
- Followers297
- Likes5.1K
Honored to present the preliminary results from the first patient enrolled in Phase I #HyDEF at @SmilowCancer at #ASTRO26. Huge credit to Dr. @AlisaRybkin for her tireless work on this study and to PI Dr. Tim Robinson for his leadership. Grateful to be part of this team.
.@JamesNinia presents the HyDEF phase I trial #ASTRO26. The protocol treats two halves of the same tumor with radiobiologically equivalent but different fractionated doses, enabling a direct intra-tumoral comparison of fractionation schedules in patients with diffuse large B-cell lymphoma bridging to CAR-T therapy.
In the first patient, tumor volume dropped 98% by day 60, T-cell strength improved post-radiation & treatment was well tolerated. @SmilowCancer @YaleRadOnc @ASTRO_org @OncoAlert
James Ninia retweeted
At #ASTRO26, we are proud to welcome so many Yale attendees, including our current residents and the alumni of our Radiation Oncology Residency Program @YaleRadOnc, all representing @YaleMed @SmilowCancer @YNHH and advancing the field of radiation oncology. @ASTRO_org @OncoAlert
James Ninia retweeted
Today at #ASTRO26, we have two AM and two PM poster presentations scheduled in Exhibit Hall A. Please stop by and support your colleagues and their research: Drs. Dae Han; Anvi Sud; @JamesNinia; and Erica Shen.
@SmilowCancer @ASTRO_org
One of my favorite projects from the past year. Grateful for the opportunity to dig into the @YNHH archives and uncover this early chapter of #brachytherapy at Yale. ⏳ ⏰ ☢️ #ASTRO26
.@JamesNinia shares a case series of early radium therapy from the @YNHH archives, the birth of modern #brachytherapy, at #ASTRO26. @ASTRO_org @YaleRadOnc @SmilowCancer @OncoAlert
amportal.astro.org/sessions/…
A little #ASTRO26 time travel. 🕰️ Presented our historic case series on radium therapy’s early implementation at @YNHH in 1922.
As we spend another great @ASTRO_org meeting excited about the future, it’s always worth looking back to see what we can learn from our history.
James Ninia retweeted
Here at #YaleRadOnc, we believe in feeding our rotating med students 🥢
Had a great time going out to Chef Jiang in New Haven for some spicy Szechuan food on Friday! #meded #medtwitter – at New Haven, CT
James Ninia retweeted
Senior med students exploring #RadOnc: join us for a virtual Yale Therapeutic Radiology Resident Meet & Greet
Sept 9, 2026 at 7:00 PM ET on Zoom
Register via the 🚨NEW🚨QR code on the flyer or the link in the reply below. #MedTwitter #RadiationOncology #MedStudent
James Ninia retweeted
Great having Dr. Kavita Dharmarajan (@kv_dharmarajan) visit Yale Therapeutic Radiology this week! We enjoyed learning from her Grand Rounds lecture on Palliative Radiation Therapy and our thoughtful discussion over lunch. Thanks for spending time with us! #RadOnc #PalliativeCare – at New Haven, CT
James Ninia retweeted
New in #practicalRO: Stepwise CSI: A Practical Approach to Urgent Palliative Focal Radiotherapy as a ‘Bridge’ to the Definitive Management of Acute Leptomeningeal Disease. tinyurl.com/proninia
James Ninia retweeted
Research spotlight from #YaleRadOnc:
Two prescriptions, one tumor.
At @RadiumSociety, @JamesNinia presented #HyDEF—a novel within-tumor trial comparing BID vs QD RT in r/r DLBCL prior to T-cell therapy.
Early results show feasible planning & delivery.
@AlisaRybkin #ARS2026
1/ New in @ClinicalLung 📢
Complete consolidative RT in ES-SCLC → ⬆️ OS & PFS
Oligometastatic status alone ≠ prognostic
🔗tinyurl.com/CCRTSCLC
@HenryParkMD @Annechiangmd @FeghaliKarine @Thomas_Hayman
#RadOnc #SCLC #RMST #ClinicalLungCancer
3/ Key insights:
📌 Oligometastatic status alone was not independently prognostic
📌 Completeness of local therapy may matter more than disease burden
📌Receiving immunotherapy was associated with improved overall survival in this cohort
4/ Main takeaway:
🎯 Treating all residual disease (when feasible) may improve outcomes in ES-SCLC
Future validation is needed — the NRG-LU007/RAPTOR trial will help evaluate these findings prospectively
#Oncology #RadOnc #LungCancer #SCLC #CancerResearch #MedTwitter
Excited to share our contribution to a #GyZone case in @IJROBP on oligoprogressive MET NSCLC. In this challenging scenario, we advocate for thoughtful nodal RT while maintaining systemic therapy. Grateful to work with @HenryParkMD! authors.elsevier.com/a/1mxzu…
James Ninia retweeted
We are so excited to welcome the Yale Therapeutic Radiology Class of 2031! 🎉⚡️🧬
We’re truly excited to have this outstanding group join our community.
#Match2026 #RadOnc #YaleRadOnc
James Ninia retweeted
Honored to host Dr. @BobTimmermanMD for the 2nd annual @RoyHDecker Memorial Lectureship at Yale.
A fitting speaker to honor one of SABR's early trailblazers, and a thought-provoking look at the future of ablative radiotherapy. #YaleRadOnc #RadOnc #PULSAR
James Ninia retweeted
Yesterday: in-service exam day for all RadOnc residents. 📚
A chance to learn more, challenge ourselves, and perhaps most importantly, continue our annual tradition of lunch together afterward. Great food with even better company. 🍛
#YaleRadOnc
Urgent palliative RT for leptomeningeal disease doesn’t have to close the door on definitive CSI.
Our new article in #PracticalRO introduces Stepwise CSI: a practical, 3-phase bridge approach from emergency palliation to definitive CSI. Check it out: tinyurl.com/StepwiseCSI